Although cisplatin-based chemotherapy concurrent with RT is a standard treatment modality for advanced-stage cervical cancer, many physicians are still reluctant to treat the intermediate-risk group with CCRT.
Phase III clinical trials based on 2D-CRT have confirmed that concurrent chemoradiotherapy can improve treatment outcomes and has been regard as standard treatment modality for locoregionally advanced NPC [14]– [14].
Since prognoses are dismal for advanced or metastatic tumors [ 6], the development of a suitable model for testing new treatment modalities for HCC is urgently required.
(for advanced users only).
And while imaging modalities have advanced the ability to detect early disease, challenges still exist for both clinician and patient.
New imaging modalities have advanced to the point of high resolution, three-dimensional analysis of tissue anatomy, composition and perfusion.
In summary, understanding various cellular and molecular pathways altered in patients with high myopia is essential in any attempts to block myopic growth, and hence can be useful in advancing treatment modalities for myopia.
Despite advancements in medicine, modalities to cure advanced diseases are often not available.
Radiotherapy (RT) is the primary treatment modality for inoperable, locally advanced non-small-cell lung cancer (NSCLC), but even with highly conformal treatment planning, radiation pneumonitis (RP) remains the most serious, dose-limiting complication.
Radiotherapy (RT) is the most important treatment modality for inoperable, locally advanced non-small-cell lung cancer (NSCLC), but conventional RT with doses in the range of 60 70 Gy is often insufficient to eradicate the tumour, with local control rates of only 10 20% at one year [1], [2].
